SCHEMBL932499

SCHEMBL932499

COc1ncc(F)cc1C1CCCN1c1ccn2ncc(C(=O)O)c2n1

nearest known ligand 0.84

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 20/20 0.84
JAK2 O60674 19/20 0.84
JAK1 P23458 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932720 1.00 NTRK1 (0.84) NTRK1JAK2JAK1
SCHEMBL2694695 0.93 NTRK1 (0.81) NTRK1JAK2JAK1
SCHEMBL2694687 0.93 NTRK1 (0.81) NTRK1JAK2JAK1
SCHEMBL2697125 0.91 NTRK1 (1.00) NTRK1JAK2JAK1
SCHEMBL19547427 0.91 NTRK1 (1.00) NTRK1JAK2JAK1
SCHEMBL2697130 0.91 NTRK1 (1.00) NTRK1JAK2JAK1
SCHEMBL19813158 0.91 NTRK1 (0.86) NTRK1JAK2JAK1
SCHEMBL1045338 0.91 NTRK1 (0.86) NTRK1JAK2JAK1
SCHEMBL1045335 0.91 NTRK1 (0.86) NTRK1JAK2JAK1
SCHEMBL18783276 0.90 NTRK1 (0.77) NTRK1JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4420732-A2 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG Pharmaceutical Co., Ltd. (KR) 2024-08-28 EP disclosed
EP-3233863-B1 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG PHARMACEUTICAL CO LTD (KR) 2024-04-10 EP disclosed
US-11597729-B2 Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2023-03-07 US disclosed
US-11091486-B2 Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof ARRAY BIOPHARMA, INC (US) 2021-08-17 US disclosed
US-20210094953-A1 TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2021-04-01 US disclosed
US-20200291026-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. 2020-09-17 US disclosed
EP-3700576-A1 FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR Array Biopharma Inc. (US) 2020-09-02 EP disclosed
US-10758542-B2 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-09-01 US disclosed
US-20200216451-A1 PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF ARRAY BIOPHARMA, INC. 2020-07-09 US disclosed
US-10647730-B2 Macrocyclic compounds as TRK kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-05-12 US disclosed
US-20150031667-A1 Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors ARRAY BIOPHARMA, INC. 2015-01-29 US disclosed
US-8933084-B2 Macrocyclic compounds as Trk kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-01-13 US disclosed
EP-2571883-B1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-01-07 EP disclosed
US-8791123-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-07-29 US disclosed
US-20130203776-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2013-08-08 US disclosed
EP-2571883-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS Array Biopharma, Inc. (US) 2013-03-27 EP disclosed
EP-2451812-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS Array Biopharma, Inc. (US) 2012-05-16 EP disclosed
US-20120108568-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-05-03 US disclosed
WO-2011146336-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-11-24 WO disclosed
WO-2011006074-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203776-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K3 NTRK1 31/4885JAK2 127/4885JAK1 460/4885
US-20210094953-A1 TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF MUSK, TPM4, TPM3 NTRK1 21/4885JAK2 763/4885JAK1 203/4885
US-20200291026-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K3 NTRK1 31/4885JAK2 127/4885JAK1 460/4885
US-11091486-B2 Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof DPYD, TYMP, UMPS NTRK1 4624/4885JAK2 451/4885JAK1 121/4885
US-11597729-B2 Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof MUSK, TPM4, TPM3 NTRK1 21/4885JAK2 763/4885JAK1 203/4885
US-20120108568-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS FRK, TXK, TNNI3K NTRK1 8/4885JAK2 143/4885JAK1 137/4885
US-10647730-B2 Macrocyclic compounds as TRK kinase inhibitors MAP3K20, MAP3K1, MAP3K3 NTRK1 27/4885JAK2 100/4885JAK1 417/4885
US-20150031667-A1 Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors TXK, FRK, LTK NTRK1 7/4885JAK2 124/4885JAK1 139/4885
US-20200216451-A1 PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF DPYD, TYMP, UMPS NTRK1 4624/4885JAK2 451/4885JAK1 121/4885
US-10758542-B2 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors LTK, TXK, FRK NTRK1 7/4885JAK2 133/4885JAK1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.